How many insider trades does FilingIQ track for CLSD?

FilingIQ tracks 193 Form 4 insider transactions for CLSD (Clearside Biomedical, Inc.), covering filings from Jun 7, 2016 onwards. 0 of those were filed in the last 90 days.

Are CLSD insiders net buyers or net sellers?

Across the full Form 4 history for CLSD, 46 transactions (24%) were open-market purchases and 101 (52%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CLSD insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CLSD in?

Clearside Biomedical, Inc. (CLSD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.15M.

CLSD insider trading

NasdaqGM Healthcare

Clearside Biomedical, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

193

Last 90 days

Buys / sells

24% / 52%

Market cap

$2.15M

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Company website: clearsidebio.com

CLSD insider activity at a glance

FilingIQ has scored 193 insider transactions for CLSD since Jun 7, 2016. The most recent filing in our index is dated Feb 24, 2025.

Across the full history, 46 open-market purchases and 101 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CLSD insider trades is 54.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CLSD trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 805

UNITED THERAPEUTICS Corp

BLLN 188

BillionToOne, Inc.

KYMR 166

Kymera Therapeutics, Inc.

THERMO FISHER SCIENTIFIC INC.

HNGE 122

Hinge Health, Inc.

GH 120

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for CLSD?: FilingIQ tracks 193 Form 4 insider transactions for CLSD (Clearside Biomedical, Inc.), covering filings from Jun 7, 2016 onwards. 0 of those were filed in the last 90 days.
Are CLSD insiders net buyers or net sellers?: Across the full Form 4 history for CLSD, 46 transactions (24%) were open-market purchases and 101 (52%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CLSD insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CLSD in?: Clearside Biomedical, Inc. (CLSD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.15M.

Methodology & sources

Every CLSD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.